Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2011-08-02
2011-08-02
Ouspenski, Ilia (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Reexamination Certificate
active
07988965
ABSTRACT:
Immunization of human antibody-producing transgenic mice, which have been created using genetic engineering techniques, with AILIM molecule as an antigen resulted in various human monoclonal antibodies capable of binding to AILIM and capable of controlling a variety of biological reactions (for example, cell proliferation, cytokine production, immune cytolysis, cell death, induction of ADCC, etc.) associated with AILIM-mediated costimulatory signal (secondary signal) transduction. Furthermore, it has been revealed that the human monoclonal antibody is effective to treat and prevent various diseases associated with AILIM-mediated costimulatory signal transduction, being capable of inhibiting the onset and/or advancement of the diseases.
REFERENCES:
patent: 5484892 (1996-01-01), Tedder et al.
patent: 5506126 (1996-04-01), Seed et al.
patent: 5521288 (1996-05-01), Linsley et al.
patent: 5747461 (1998-05-01), Markov
patent: 5770197 (1998-06-01), Linsley et al.
patent: 5914112 (1999-06-01), Bednar et al.
patent: 6075181 (2000-06-01), Kucherlapati et al.
patent: 6297022 (2001-10-01), McDonnell et al.
patent: 6451305 (2002-09-01), Boussiotis et al.
patent: 6531505 (2003-03-01), Xu et al.
patent: 6803039 (2004-10-01), Tsuji et al.
patent: 7030225 (2006-04-01), Tamatani et al.
patent: 7045615 (2006-05-01), Tamatani et al.
patent: 7112655 (2006-09-01), Tamatani et al.
patent: 7166283 (2007-01-01), Tsuji et al.
patent: 7196175 (2007-03-01), Tamatani et al.
patent: 7217792 (2007-05-01), Tamatani et al.
patent: 2002/0115831 (2002-08-01), Tamatani et al.
patent: 2002/0151685 (2002-10-01), Tamatani et al.
patent: 2002/0156242 (2002-10-01), Tamatani et al.
patent: 2002/0164697 (2002-11-01), Coyle et al.
patent: 2002/0177191 (2002-11-01), Kroczek
patent: 2002/0182667 (2002-12-01), Kroczek
patent: 2003/0083472 (2003-05-01), Tamatani et al.
patent: 2004/0120945 (2004-06-01), Tamatani et al.
patent: 2004/0131608 (2004-07-01), Watanabe
patent: 2004/0132658 (2004-07-01), Tamatani et al.
patent: 2004/0146506 (2004-07-01), Tamatani et al.
patent: 2004/0146991 (2004-07-01), Tsuji et al.
patent: 2004/0151669 (2004-08-01), Tamatani et al.
patent: 2004/0151720 (2004-08-01), Tamatani et al.
patent: 2004/0229788 (2004-11-01), Tamatani et al.
patent: 2004/0229790 (2004-11-01), Tezuka et al.
patent: 2004/0253229 (2004-12-01), Suzuki et al.
patent: 13320/99 (1999-04-01), None
patent: 2293666 (1998-12-01), None
patent: 19821060 (1999-04-01), None
patent: 0984023 (2000-03-01), None
patent: 1 125 585 (2001-08-01), None
patent: 5-72204 (1993-03-01), None
patent: 11-228442 (1999-08-01), None
patent: 2000-154151 (2000-06-01), None
patent: WO 95/33770 (1995-12-01), None
patent: WO 97/26912 (1997-07-01), None
patent: WO 98/11909 (1998-03-01), None
patent: WO 98/19706 (1998-05-01), None
patent: WO 98/37415 (1998-08-01), None
patent: WO 98/38216 (1998-09-01), None
patent: WO 98/45331 (1998-10-01), None
patent: WO 99/15553 (1999-04-01), None
patent: WO 00/19988 (2000-04-01), None
patent: WO 00/46240 (2000-08-01), None
patent: WO 00/67788 (2000-11-01), None
patent: WO 01/08700 (2001-02-01), None
patent: WO 01/12658 (2001-02-01), None
patent: WO 01/15732 (2001-03-01), None
patent: WO 01/18022 (2001-03-01), None
patent: WO 01/21796 (2001-03-01), None
patent: WO 01/32675 (2001-05-01), None
patent: WO 01/64704 (2001-09-01), None
patent: WO 01/87981 (2001-11-01), None
patent: WO 02/44364 (2002-06-01), None
patent: WO 02/70010 (2002-09-01), None
patent: WO 02/76504 (2002-10-01), None
Blazer et al., J. Immunol., 1996, 157: 3250-3259.
Odegard et al. (2009) J. immunol. 182: 4076-4084 (provided by Applicant).
Kawamoto et al. (2006) Arthritis Res. Therapy 8:R62 (14 pages; provided by Applicant).
Abbas, “T-cell stimulation: an abundance of B7s,” Nat Med. 5(12):1345-6 (1999).
Aicher et al., “Characterization of Human Inducible Costimulator Ligand Expression and Function,” J. Immunol., 164(9):4689-4696 (2000).
Bajorath, “A molecular model of inducible costimulator protein and three-dimensional analysis of its relation to the CD28 family of T cell-specific costimulatory receptors,” J. Mol. Model 5:169-176 (1999).
Beier et al., “Induction, binding specificity and function of human ICOS,” Eur. J. Immunol., 30(12):3707-3717 (2000).
Bensimon et al., “Human lupus anti-DNS autoantibodies undergo essentially primary V kappa gene rearrangements,” Embo J. 13(13):2951-62 (1994).
Brodie et al., “LICOS, a primordial costimulatory ligand?,” Curr. Biol., 10(6):333-336 (2000).
Buonfiglio et al., “Characterization of a novel human surface molecule selectively expressed by mature thymocytes, activated T cells and subsets of T cell lymphomas,” Eur. J. Immunol., 29(9)2863-2874 (1999).
Buonfiglio et al., “The T cell activation molecule H4 and the CD28-like molecule ICOS are identical,” Eur. J. Immunol. 30(12):3463-3467 (2000).
Cameron “Recent advances in transgenic technology” Molecular Biotechnology 7:253-65 (1997).
Campbell et al., “Separable effector T cell populations specialized for B cell help or tissue inflammation,” Nat Immunol. 2(9):876-81 (2001).
Chambers, “The expanding world of co-stimulation: the two-signal model revisited,” Trends in Immunology, 22(4):217-223 (2001).
Chaouat, G. et al., (1995), “IL-10 Prevents Naturally Occuring Fetal Loss in the CBA x DBA/2 Mating Combination, and Local Defect in IL-10 Production in This Abortion-Prone Combination Is Corrected by in Vivo Injection of IFN-τ1,”J. Immunol,154:4261-4268.
Chapoval et al., “B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production,” Nat Immunol. 2(3):269-74 (2001).
Cocks et al., “A novel receptor involved in T-cell activation,” Nature, 376:260-263 (1995).
Coyle et al., “The CD28-Related Molecule ICOS Is Required for Effective T Cell-Dependent Immune Responses,” Immunity 13(1):95-105 (2000).
Dong et al., “B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion,” Nat. Med. 5(12):1365-9 (1999).
Dong et al., “Cutting Edge: Critical Role of Inducible Costimulator in Germinal Center Reactions,” J. Immunol., 166(6):3659-3662 (2001).
Dong, “ICOS co-stimulatory receptor is essential for T-cell activation and function,” Nature 409(6816):97-101 (2001).
Eljaschewitsch et al., “Identification of a novel activation antigen on human CD4+ T cells,” Immunobiol., 194(1-3):27 (1995).
Goding, “Monoclonal Antibodies: Principles and Practice,” 2ndEdition, Academic Press, Orlando, Florida, Chapter 8, pp. 281-293 (1986).
Goni et al., “Structural and idiotypic characterization of the L chains of human IgM autoantibodies with different specificities,” J. Immunol. 142(9):3158-63 (1989).
Gonzalo et al., “Cutting Edge: The Related Molecules CD28 and Inducible Costimulator Deliver Both Unique and Complementary Signals Required for Optimal T Cell Activation,” J. Immunol., 166(1):1-5 (2001).
Gonzalo et al., “ICOS is critical for T helper cell-mediated lung mucosal inflammatory responses,” Nat Immunol. 2(7):597-604 (2001).
Guo et al., “Stimulatory Effects of B7-Related Protein-1 on Cellular and Humoral Immune Responses in Mice,” J. Immunol., 166(9):5578-5584 (2001).
Hanzawa et al., “Characteristics of a TTH1 antibody which blocks an unknown adhesion phenomenon,” Proceedings of the Japanese Society for Immunology, vol. 24, Abstract No. W17-13 (1994) [Original Japanese and English Language Translation].
Harlow and Lane, “Antibodies: A Laboratory Manual,” Cold Spring Harbor Laboratory, p. 285 (1988).
Heyeck et al., “Developmental regulation of a murine T-cell-specific tyrosine kinase gene, Tsk,” Proc. Natl. Acad. Sci. USA, 90:669-673 (1993).
Houdebine “Production of pharmaceutical proteins from transgenic animals” J. Biotechnol. 34:269-87 (1994).
Hutloff e
Hori Nobuaki
Tezuka Katsunari
Tsuji Takashi
Fish & Richardson P.C.
Japan Tobacco Inc.
Ouspenski Ilia
LandOfFree
Methods of treating systemic lupus erythematosus with an... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating systemic lupus erythematosus with an..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating systemic lupus erythematosus with an... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2641191